{
  "main_header": {
    "sid": 1002925,
    "name": "Medico Remedies",
    "stock_name": "Medico Remedies",
    "full_name": "Medico Remedies Ltd",
    "name_url": "stocks-analysis/medico-remedies",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "57.78",
    "chg": -0.05,
    "chgp": "-0.09%",
    "dir": -1,
    "prev_price": "57.83",
    "mcapval": "479.48 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540937,
    "symbol": "MEDICO",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE630Y01024",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "23:59 PM",
    "bse_nse_vol": "94.29 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medico-remedies-1002925-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Medico Remedies Adjusts Valuation Amidst Competitive Pharmaceuticals Landscape and Declining Stock Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medico-remedies-valuation-grade-downgraded-from-very-expensive-to-expensive-1462669",
        "imagepath": "",
        "date": "2025-03-19 08:00:58",
        "description": "Medico Remedies, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 50.62, reflecting a decline from the previous close of 52.57. Over the past year, Medico Remedies has experienced a significant drop of 34.86%, contrasting with a modest gain of 3.51% in the Sensex during the same period.\n\nKey financial metrics for Medico Remedies include a PE ratio of 47.47 and an EV to EBITDA ratio of 33.12, indicating a premium valuation compared to its peers. In comparison, Shree Ganesh Remedies, also classified as expensive, has a PE ratio of 31.84 and an EV to EBITDA of 20.29. Other competitors like Kopran and Anuh Pharma show more attractive valuations with lower PE ratios and EV to EBITDA figures, suggesting a more favorable market position.\n\nDespite the recent valuation adjustment, Medico Remedies maintains a return on capita..."
      },
      {
        "title": "Medico Remedies Faces Stagnation Amid Declining Promoter Confidence and Flat Sales Growth",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-downgraded-to-sell-amid-flat-financial-performance-and-stake-reduction-1423795",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/MedicoRemedies_mojoScore_682615.png",
        "date": "2025-03-18 08:22:35",
        "description": "Medico Remedies, a microcap in the Pharmaceuticals & Drugs sector, has experienced a recent evaluation adjustment amid flat financial performance for Q3 FY24-25. The company reported a modest annual growth rate in net sales and a significant reliance on non-operating income, raising concerns about future prospects and promoter confidence."
      },
      {
        "title": "Medico Remedies Reports Stable Q3 FY24-25 Results Amid Concerns Over Income Sources",
        "link": "https://www.marketsmojo.com/news/result-analysis/medico-remedies-reports-q3-fy24-25-pat-of-rs-2-62-crore-up-80-7-year-on-year-751350",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/MedicoRemedies_quaterlyResult_370284.png",
        "date": "2025-02-05 18:47:49",
        "description": "Medico Remedies has announced its financial results for Q3 FY24-25, showing a Profit After Tax of Rs 2.62 crore, an 80.7% year-on-year increase. Net sales reached Rs 39.49 crore, up 32.65% from the previous year. However, a significant portion of income comes from non-operating activities, raising sustainability concerns."
      },
      {
        "title": "Medico Remedies Faces Financial Challenges Amid Declining Sales and Stake Reduction in Q2 FY24",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-reports-q2-fy24-25-net-sales-decline-of-7-11-to-rs-39-35-crore-337414",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/1/MedicoRemedies_mojoScore_253696.png",
        "date": "2025-01-27 19:18:24",
        "description": "Medico Remedies, a microcap in the Pharmaceuticals & Drugs sector, has faced a challenging second quarter in FY24, with declines in key financial metrics including operating cash flow and net sales. The company has underperformed the broader market, raising concerns about its profitability and management confidence."
      }
    ],
    "total": 30,
    "sid": "1002925",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/medico-remedies-1002925"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Director",
      "datetime": "09-Apr-2025",
      "details": "Please find attached Intimation for Resignation of Mr. Dayanand Mathapati as Executive Director.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "08-Apr-2025",
      "details": "Please find attached Intimation for Receipt of Order.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "03-Apr-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Haresh Kapurlal Mehta",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Medico Remedies Ltd has announced <strong>2:10</strong> stock split, ex-date: 16 Mar 23",
          "dt": "2023-03-16",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Medico Remedies Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 16 Nov 21",
          "dt": "2021-11-16",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Medico Remedies Adjusts Valuation Amidst Competitive Pharmaceuticals Landscape and Declining Stock Performance

2025-03-19 08:00:58

Medico Remedies, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 50.62, reflecting a decline from the previous close of 52.57. Over the past year, Medico Remedies has experienced a significant drop of 34.86%, contrasting with a modest gain of 3.51% in the Sensex during the same period. Key financial metrics for Medico Remedies include a PE ratio of 47.47 and an EV to EBITDA ratio of 33.12, indicating a premium valuation compared to its peers. In comparison, Shree Ganesh Remedies, also classified as expensive, has a PE ratio of 31.84 and an EV to EBITDA of 20.29. Other competitors like Kopran and Anuh Pharma show more attractive valuations with lower PE ratios and EV to EBITDA figures, suggesting a more favorable market position. Despite the recent valuation adjustment, Medico Remedies maintains a return on capita...

Read More

Medico Remedies Faces Stagnation Amid Declining Promoter Confidence and Flat Sales Growth

2025-03-18 08:22:35

Medico Remedies, a microcap in the Pharmaceuticals & Drugs sector, has experienced a recent evaluation adjustment amid flat financial performance for Q3 FY24-25. The company reported a modest annual growth rate in net sales and a significant reliance on non-operating income, raising concerns about future prospects and promoter confidence.

Read More

Medico Remedies Reports Stable Q3 FY24-25 Results Amid Concerns Over Income Sources

2025-02-05 18:47:49

Medico Remedies has announced its financial results for Q3 FY24-25, showing a Profit After Tax of Rs 2.62 crore, an 80.7% year-on-year increase. Net sales reached Rs 39.49 crore, up 32.65% from the previous year. However, a significant portion of income comes from non-operating activities, raising sustainability concerns.

Read More

Medico Remedies Faces Financial Challenges Amid Declining Sales and Stake Reduction in Q2 FY24

2025-01-27 19:18:24

Medico Remedies, a microcap in the Pharmaceuticals & Drugs sector, has faced a challenging second quarter in FY24, with declines in key financial metrics including operating cash flow and net sales. The company has underperformed the broader market, raising concerns about its profitability and management confidence.

Read More

View All News